{"component": "definition", "props": {"groups": [{"snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "primary-endpoints", "type": "clause", "offset": [44, 61]}, {"key": "determination-of", "type": "clause", "offset": [72, 88]}, {"key": "preliminary-determination", "type": "definition", "offset": [110, 135]}, {"key": "as-amended", "type": "definition", "offset": [220, 230]}, {"key": "from-time-to-time", "type": "clause", "offset": [231, 248]}, {"key": "foreign-equivalent", "type": "definition", "offset": [258, 276]}], "size": 43, "snippet": "means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. \u00a7 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.", "samples": [{"hash": "emr8ABMPfIp", "uri": "/contracts/emr8ABMPfIp#phase-ii-study", "label": "Licensing Agreement", "score": 35.3063354492, "published": true}, {"hash": "9k1MaVJP2On", "uri": "/contracts/9k1MaVJP2On#phase-ii-study", "label": "License Agreement (CinCor Pharma, Inc.)", "score": 32.9589309692, "published": true}, {"hash": "j9bbB4YgprD", "uri": "/contracts/j9bbB4YgprD#phase-ii-study", "label": "Collaboration and License Agreement (Blueprint Medicines Corp)", "score": 32.5701560974, "published": true}], "hash": "ace75751e98f7e84658a9f53bad5fbe9", "id": 1}, {"snippet_links": [{"key": "the-safety", "type": "clause", "offset": [27, 37]}, {"key": "further-defined", "type": "clause", "offset": [81, 96]}, {"key": "outside-the-united-states", "type": "definition", "offset": [149, 174]}], "size": 35, "snippet": "means a study in humans of the safety, dose ranging or efficacy of a product, as further defined in 21 C.F.R. \u00a7 312.21(b) (or the equivalent thereof outside the United States).", "samples": [{"hash": "toyNMkJhal", "uri": "/contracts/toyNMkJhal#phase-ii-study", "label": "License and Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 34.1444206238, "published": true}, {"hash": "8wkFXVcAmCH", "uri": "/contracts/8wkFXVcAmCH#phase-ii-study", "label": "Development and Marketing Agreement", "score": 27.0520191193, "published": true}, {"hash": "b65cQfGV73d", "uri": "/contracts/b65cQfGV73d#phase-ii-study", "label": "Master Collaboration Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 25.3504447937, "published": true}], "hash": "563d8acbbf651917f0eb6d5980dd074f", "id": 2}, {"snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "duration-of", "type": "clause", "offset": [88, 99]}, {"key": "to-generate", "type": "definition", "offset": [112, 123]}, {"key": "evidence-of", "type": "definition", "offset": [124, 135]}, {"key": "safety-and", "type": "definition", "offset": [145, 155]}, {"key": "patient-population", "type": "clause", "offset": [225, 243]}, {"key": "clinical-study", "type": "definition", "offset": [258, 272]}, {"key": "relevant-regulatory-authorities", "type": "definition", "offset": [291, 322]}, {"key": "from-time-to-time", "type": "clause", "offset": [324, 341]}, {"key": "applicable-law", "type": "clause", "offset": [355, 369]}, {"key": "for-example", "type": "definition", "offset": [394, 405]}, {"key": "as-amended", "type": "definition", "offset": [454, 464]}, {"key": "the-non", "type": "clause", "offset": [469, 476]}, {"key": "united-states", "type": "definition", "offset": [477, 490]}], "size": 31, "snippet": "means a human clinical trial intended to explore a variety of doses, dose response, and duration of effect, and to generate evidence of clinical safety and effectiveness for a particular Indication or Indications in a target patient population, or a similar clinical study prescribed by the relevant Regulatory Authorities, from time to time, pursuant to applicable Law or otherwise, including for example the trials referred to in 21 C.F.R. \u00a7312.21(b), as amended (or the non-United States equivalent thereof).", "samples": [{"hash": "93Qux0ZY5S9", "uri": "/contracts/93Qux0ZY5S9#phase-ii-study", "label": "Collaborative Development and Commercialization Agreement", "score": 32.0863380432, "published": true}, {"hash": "5YFAqh06tTr", "uri": "/contracts/5YFAqh06tTr#phase-ii-study", "label": "Collaborative Development and Commercialization Agreement (Histogen Inc.)", "score": 31.8199863434, "published": true}, {"hash": "9GLdmDC2Q3U", "uri": "/contracts/9GLdmDC2Q3U#phase-ii-study", "label": "Master Research and Collaboration Agreement (Agios Pharmaceuticals Inc)", "score": 27.6009578705, "published": true}], "hash": "1e07b670f0d4cb9e680b7ae94b7773e7", "id": 3}, {"snippet_links": [{"key": "human-clinical-trial", "type": "definition", "offset": [8, 28]}, {"key": "the-requirements", "type": "clause", "offset": [63, 79]}, {"key": "as-amended", "type": "definition", "offset": [104, 114]}, {"key": "the-fda", "type": "clause", "offset": [150, 157]}, {"key": "phase-iii-study", "type": "definition", "offset": [179, 194]}, {"key": "phase-iv-study", "type": "definition", "offset": [198, 212]}], "size": 17, "snippet": "means a human clinical trial in any country that would satisfy the requirements of 21 C.F.R. 312.21(b) (as amended) (whether or not such trial is for the FDA), but which is not a Phase III Study or Phase IV Study.", "samples": [{"hash": "1N02hFiwTAq", "uri": "/contracts/1N02hFiwTAq#phase-ii-study", "label": "License Agreement (Zai Lab LTD)", "score": 28.6194381714, "published": true}, {"hash": "85ty2DnuFGi", "uri": "/contracts/85ty2DnuFGi#phase-ii-study", "label": "License Agreement (Zai Lab LTD)", "score": 28.4852848053, "published": true}, {"hash": "jxGFifK8dNk", "uri": "/contracts/jxGFifK8dNk#phase-ii-study", "label": "Collaboration and License Agreement (Ra Pharmaceuticals, Inc.)", "score": 27.7816562653, "published": true}], "hash": "40524f1841b29a5c4a32ba71e30b1b46", "id": 4}, {"snippet_links": [{"key": "duration-of", "type": "clause", "offset": [45, 56]}, {"key": "safety-study", "type": "clause", "offset": [124, 136]}, {"key": "the-target", "type": "clause", "offset": [153, 163]}, {"key": "patient-population", "type": "clause", "offset": [164, 182]}, {"key": "clinical-trial", "type": "clause", "offset": [216, 230]}], "size": 16, "snippet": "means (a) a dose exploration, dose response, duration of effect, kinetics, dynamic relationship or preliminary efficacy and safety study of a Product in the target patient population or (b) a controlled dose-ranging clinical trial to evaluate further the efficacy and safety of a Product in the target patient population and to define the optimal dosing regimen.", "samples": [{"hash": "5QYW98yfg01", "uri": "/contracts/5QYW98yfg01#phase-ii-study", "label": "Development, Manufacturing and Supply Agreement (TEKMIRA PHARMACEUTICALS Corp)", "score": 23.0807666779, "published": true}, {"hash": "dUwQmqpllRy", "uri": "/contracts/dUwQmqpllRy#phase-ii-study", "label": "Development, Manufacturing and Supply Agreement (Tekmira Pharmaceuticals Corp)", "score": 22.4182071686, "published": true}, {"hash": "f5n27JjLeQ7", "uri": "/contracts/f5n27JjLeQ7#phase-ii-study", "label": "Development, Manufacturing and Supply Agreement (Alnylam Pharmaceuticals, Inc.)", "score": 22.1307315826, "published": true}], "hash": "22cbe4df5318627453f21ba430e47265", "id": 5}, {"snippet_links": [{"key": "clinical-trial", "type": "clause", "offset": [8, 22]}, {"key": "to-establish", "type": "definition", "offset": [40, 52]}, {"key": "safety-and", "type": "definition", "offset": [57, 67]}, {"key": "intended-use", "type": "definition", "offset": [107, 119]}, {"key": "adverse-reactions", "type": "definition", "offset": [161, 178]}, {"key": "associated-with", "type": "definition", "offset": [188, 203]}, {"key": "the-requirements", "type": "clause", "offset": [267, 283]}, {"key": "other-jurisdiction", "type": "definition", "offset": [360, 378]}], "size": 7, "snippet": "means a clinical trial that is designed to establish the safety and preliminary efficacy of a drug for its intended use, and to define warnings, precautions and adverse reactions that are associated with the drug in the dosage range to be prescribed and that satisfy the requirements of 21 CFR 312.21(b) (or its successor regulation), or its equivalent in any other jurisdiction.", "samples": [{"hash": "7wSU09vhieX", "uri": "/contracts/7wSU09vhieX#phase-ii-study", "label": "Collaboration and License Agreement (Amgen Inc)", "score": 35.1190948486, "published": true}, {"hash": "2PhDafSC7rS", "uri": "/contracts/2PhDafSC7rS#phase-ii-study", "label": "Collaboration and License Agreement (Amgen Inc)", "score": 24.578371048, "published": true}, {"hash": "bw8hj4AaBZ0", "uri": "/contracts/bw8hj4AaBZ0#phase-ii-study", "label": "Collaboration and License Agreement (Amgen Inc)", "score": 24.1567420959, "published": true}], "hash": "8e1ccaf2dbb450ed7aad8175d61a7cd4", "id": 6}, {"snippet_links": [{"key": "licensed-product", "type": "definition", "offset": [19, 35]}, {"key": "purpose-of", "type": "clause", "offset": [61, 71]}, {"key": "determination-of", "type": "clause", "offset": [83, 99]}, {"key": "safety-and-efficacy", "type": "clause", "offset": [100, 119]}, {"key": "the-target", "type": "clause", "offset": [123, 133]}, {"key": "patient-population", "type": "clause", "offset": [134, 152]}, {"key": "to-generate", "type": "definition", "offset": [186, 197]}, {"key": "commencement-of", "type": "clause", "offset": [230, 245]}, {"key": "pivotal-trial", "type": "definition", "offset": [248, 261]}, {"key": "clinical-study", "type": "definition", "offset": [276, 290]}, {"key": "relevant-regulatory-authority", "type": "definition", "offset": [309, 338]}, {"key": "from-time-to-time", "type": "clause", "offset": [340, 357]}, {"key": "applicable-law", "type": "clause", "offset": [371, 385]}, {"key": "as-amended", "type": "definition", "offset": [458, 468]}], "size": 7, "snippet": "means a study of a Licensed Product in humans, the principal purpose of which is a determination of safety and efficacy in the target patient population, which is prospectively designed to generate sufficient data that may permit commencement of a Pivotal Trial, or a similar Clinical Study prescribed by the relevant Regulatory Authority, from time to time, pursuant to applicable law or otherwise, including the trials referred to in 21 C.F.R. \u00a7312.21(b), as amended.", "samples": [{"hash": "hWVAGZVVnqr", "uri": "/contracts/hWVAGZVVnqr#phase-ii-study", "label": "Exclusive License Agreement (Affinia Therapeutics Inc.)", "score": 33.0082130432, "published": true}, {"hash": "1CzYHXEctyp", "uri": "/contracts/1CzYHXEctyp#phase-ii-study", "label": "Exclusive License Agreement (Affinia Therapeutics Inc.)", "score": 32.8959617615, "published": true}, {"hash": "gb5lRg1Fw4l", "uri": "/contracts/gb5lRg1Fw4l#phase-ii-study", "label": "Sublicense Agreement (Akouos, Inc.)", "score": 31.4257354736, "published": true}], "hash": "2a922552b42d45484f64060bb7ba858f", "id": 7}, {"snippet_links": [{"key": "phase-ii-clinical-trial", "type": "definition", "offset": [8, 31]}, {"key": "as-prescribed", "type": "definition", "offset": [32, 45]}, {"key": "fda-regulations", "type": "definition", "offset": [60, 75]}], "size": 6, "snippet": "means a Phase II clinical trial as prescribed by applicable FDA regulations, or corresponding regulations of any comparable entity.", "samples": [{"hash": "1pgJyXuPhyy", "uri": "/contracts/1pgJyXuPhyy#phase-ii-study", "label": "Co Development and Co Commercialization Agreement", "score": 31.3408622742, "published": true}, {"hash": "fvMI8zKYVhy", "uri": "/contracts/fvMI8zKYVhy#phase-ii-study", "label": "Co Development and Co Commercialization Agreement (Alexion Pharmaceuticals Inc)", "score": 21.0, "published": true}, {"hash": "lsJTxHgnCWq", "uri": "/contracts/lsJTxHgnCWq#phase-ii-study", "label": "Collaboration Agreement (Xoma LTD /De/)", "score": 18.0, "published": true}], "hash": "238f8b9dcf5d33433adb82c47aaba4ea", "id": 8}, {"snippet_links": [{"key": "phase-iia-study", "type": "definition", "offset": [23, 38]}, {"key": "phase-iib-study", "type": "clause", "offset": [45, 60]}], "size": 5, "snippet": "means, collectively, a Phase IIa Study and a Phase IIb Study.", "samples": [{"hash": "ffApXQraajB", "uri": "/contracts/ffApXQraajB#phase-ii-study", "label": "License, Development, Commercialization and Supply Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 26.5906906128, "published": true}, {"hash": "hJeUcCE0yyK", "uri": "/contracts/hJeUcCE0yyK#phase-ii-study", "label": "License, Development, Commercialization and Supply Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 24.1827507019, "published": true}, {"hash": "cRoipUp5zOT", "uri": "/contracts/cRoipUp5zOT#phase-ii-study", "label": "License Agreement (Sucampo Pharmaceuticals, Inc.)", "score": 21.0, "published": true}], "hash": "22f13004c04febc9baaf830805c9df76", "id": 9}, {"snippet_links": [{"key": "in-respect-of", "type": "definition", "offset": [7, 20]}, {"key": "sublicensed-product", "type": "definition", "offset": [23, 42]}, {"key": "submission-and-approval-process", "type": "clause", "offset": [72, 103]}, {"key": "clinical-studies", "type": "definition", "offset": [140, 156]}, {"key": "preliminary-data", "type": "definition", "offset": [177, 193]}, {"key": "specifically-defined", "type": "clause", "offset": [265, 285]}, {"key": "rules-and-regulations", "type": "clause", "offset": [293, 314]}, {"key": "future-revisions", "type": "clause", "offset": [366, 382]}, {"key": "clinical-study", "type": "definition", "offset": [422, 436]}, {"key": "the-united-states", "type": "definition", "offset": [477, 494]}], "size": 5, "snippet": "means, in respect of a Sublicensed Product, (a) that portion of the FDA submission and approval process which provides for early controlled clinical studies conducted to obtain preliminary data on the effectiveness of a product for a particular indication, as more specifically defined by the rules and regulations of the FDA, including 21 C.F.R. \u00a7 312.21(b) or any future revisions or substitutes thereof; or (b) similar clinical study in any national jurisdiction other than the United States.", "samples": [{"hash": "9cX0w1IduWP", "uri": "/contracts/9cX0w1IduWP#phase-ii-study", "label": "Sublicense Agreement (Moleculin Biotech, Inc.)", "score": 32.9863090515, "published": true}, {"hash": "aMt9MeF5YxJ", "uri": "/contracts/aMt9MeF5YxJ#phase-ii-study", "label": "Sublicense Agreement (Moleculin Biotech, Inc.)", "score": 32.225189209, "published": true}, {"hash": "kzMpucSa7YX", "uri": "/contracts/kzMpucSa7YX#phase-ii-study", "label": "Sublicense Agreement (Moleculin Biotech, Inc.)", "score": 29.1389465332, "published": true}], "hash": "947adf0fba19de1d3db84c9500df8a25", "id": 10}], "next_curs": "ClsSVWoVc35sYXdpbnNpZGVyY29udHJhY3RzcjcLEhpEZWZpbml0aW9uU25pcHBldEdyb3VwX3Y1NiIXcGhhc2UtaWktc3R1ZHkjMDAwMDAwMGEMogECZW4YACAA", "definition": {"title": "Phase II Study", "size": 268, "snippet": "means a human clinical trial, for which the primary endpoints include a determination of dose ranges and/or a preliminary determination of efficacy in patients being studied as described in 21 C.F.R. \u00a7 312.21(b) (FDCA), as amended from time to time, and the foreign equivalent thereof.", "id": "phase-ii-study", "examples": ["Following completion of each successful <strong>Phase II Study</strong> for such Product in such Future Indication, Alexion shall provide XOMA with written notice of such completion and enclose a copy of a summary analysis performed in accordance with the pre-specified statistical analysis plan filed with the FDA.", "Following completion of each successful <strong>Phase II Study</strong> for such Product in such Future Indication, XOMA shall provide Alexion with written notice of such completion and enclose a copy of a summary analysis performed in accordance with the pre-specified statistical analysis plan filed with the FDA.", "Upon expiration of this Agreement pursuant to Section 13.1, provided that Alexion has at the time of expiration completed a <strong>Phase II Study</strong> for a Product in any Future Indication which XOMA has not Opted Back In to prior to such expiration, Alexion shall have an exclusive (even as to XOMA), sublicensable license under the XOMA Technology to use, develop, make, have made, sell, have sold, offer for sale, import and export Products only for such Future Indication(s) in the Territory.", "Following completion of each such <strong>Phase II Study</strong>, XOMA shall provide Alexion with written notice of such completion and enclose a copy of a summary analysis performed in accordance with the pre-specified statistical analysis plan filed with the FDA.", "Within twenty (20) days after the execution of this Agreement, Seller shall commission a qualified engineering firm to conduct a <strong>Phase II Study</strong> for the Parcel of Owned Property designated as Item 2 on Schedule 3.15 and an asbestos study for each Parcel of Owned Property.", "The Phase I Study, the asbestos study and the <strong>Phase II Study</strong> are each sometimes hereinafter referred to as a &quot;Study.&quot; The cost of each Study shall be borne equally by Seller and Buyer.", "In the alternative, Alexion may permit XOMA to conduct a <strong>Phase II Study</strong> for a proposed Future Indication at XOMA&#x27;s sole cost and risk but Alexion shall have the right, in its sole discretion, to exercise its Right of Prohibition after completion of each such <strong>Phase II Study</strong>.", "Furthermore, Pieris shall annually inform Roche on the development progress of such [***] until completion of the first <strong>Phase II Study</strong>.", "Roche will use Commercially Reasonable Efforts, to the extent reasonably practicable, to permit BPM to have, at BPM\u2019s expense, one (1) mutually acceptable representative of BPM attend, solely as a non-participating observer, material, substantive meetings, including pre-IND and end of <strong>Phase II Study</strong> meetings, with the Regulatory Authorities pertaining to all Licensed Products in Program 2 or Program 4.", "If Genmab accepts the proposal made by CureVac for supplies of Product for the first Clinical <strong>Phase II Study</strong> and is agreeable to appoint CureVac, the Parties shall within [*****] negotiate in good faith a master services agreement (\u201cMSA\u201d) and related quality agreement and a first work order for the Manufacture and supply of such Product quantities, Manufactured to the specifications specified by Genmab, and for payment [*****] on customary market-based terms."], "related": [["phase-iii-study", "Phase III Study", "Phase III Study"], ["phase-i-study", "Phase I Study", "Phase I Study"], ["phase-ii-trial", "Phase II Trial", "Phase II Trial"], ["phase-ii-clinical-study", "Phase II Clinical Study", "Phase II Clinical Study"], ["phase-ii-clinical-trial", "Phase II Clinical Trial", "Phase II Clinical Trial"]], "related_snippets": [], "updated": "2025-11-14T05:22:25+00:00"}, "json": true, "cursor": ""}}